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Abstract 
MicroRNA (miR)-155 and cyclooxygenase (COX)-2 are both elevated in numerous cancers including 
colorectal cancer. MiR-155 enhances COX-2 expression and is an established regulator of epithelial-
mesenchymal transition and inflammation. Inhibition of miR-155 or COX-2 exhibit similar negative 
effects on tumorigenicity. Thus, it is hypothesized that miR-155 may be a promising target for 
antagonizing COX-2 expression in colorectal and other cancers. 
Introduction 
Nonsteroidal anti-inflammatory drugs enhance cancer survival rates by promoting tumor regression in 
animal models and human studies of colon cancer [Wang et al., 2005]. They function, in part, by 
inhibiting cyclooxygenase (COX) production of the eicosanoid precursor, prostaglandin H2. COX 
enzymes exist in two isoforms encoded on two distinct genes, COX-1 (PTGS1) and COX-2 (PTGS2), 
although a splice variant encoded by PTGS1, termed COX-3 has been reported [Shaftel et al., 2003]. 
COX-1 is constitutively expressed in most cells while COX-2 is typically not expressed under 
physiological conditions. COX-2 expression is induced by a variety of extracellular stimuli including 
cytokines, chemokines, and growth factors. 
COX-2 in Cancer 
COX-2 exhibits elevated expression in colorectal cancer [Eberhart et al., 1994; Sano et al., 1995]. Clinical 
studies demonstrate that COX-2 inhibition greatly reduces the risk of colorectal cancer [Smalley and 
DuBois, 1997]. In addition, COX-2 is expressed at high levels in breast cancer and lung cancer [Parrett et 
al., 1997; Wolff et al., 1998]. These studies indicate that dysregulation of COX-2 gene expression may 
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exist in colorectal and other cancers. Recently, investigations into COX-2 dysregulation in colorectal 
cancer have focused on post-transcriptional regulation. 
In colorectal cancer, dysregulation of COX-2 post-transcriptional regulation by AU-rich element binding 
proteins and miRNAs is well documented [Young and Dixon, 2010; Dixon et al., 2013]. MicroRNAs 
(miRNAs) are dysregulated in numerous diseases including cancer. Validated human miRNAs that target 
COX-2 for miRNA-mediated repression include miR-146a/b [Sato et al., 2010; Comer et al., 2014], miR-
16 [Young et al., 2012], miR-143 [Kim et al., 2011], miR-199a-3p [Akhtar and Haqqi, 2012], miR-26a [Ji 
et al., 2010], and miR-101a [Tanaka et al., 2009]. Thus, a number of miRNAs have been validated as 
post-transcriptional regulators of COX-2. miR-155 expression positively correlates with COX-2 
expression in cancer and is elevated in numerous cancers including colorectal cancer, lymphomas, breast 
cancer, and lung cancer [Kluiver et al., 2005; Volinia et al., 2006; Wang et al., 2012]. miR-155 is encoded 
by the oncogenic BIC gene [Eis et al., 2005]. An extensive review of miR-155 function in cancer is 
beyond the scope of this mini-review, thus the readers are referred to Chen et al. [2014]. 
In brief, miR-155 is a p53 regulated, transforming growth factor-β, and pro-inflammatory mediator- 
induced miRNA that promotes epithelial-mesenchymal transition by regulating numerous genes including 
Ras homolog gene family member A and CCAAT/enhancer-binding protein-β [Kong et al., 2008; 
Johansson et al., 2013; Basova et al., 2014]. miR-155 has been extensively studied in the immunology 
field, as it is a major regulator of the immune response [Vigorito et al., 2013]. miR-155 enhances COX-2 
gene expression in human airway smooth muscle cells [Comer et al., 2015]. In addition, miR-155 
enhances expression of COX-2 in murine macrophages [Lee et al., 2011]. The mechanism responsible for 
miR-155 enhancement of COX-2 has not been determined, but it may involve miR-155-mediated 
repression of suppressor of cytokine signaling-1 or phosphatidylinositol-3,4,5-triphosphate 5 phosphatase 
(SHIP1) [O'Connell et al., 2009; Jiang et al., 2010]. Repression of SHIP1 may lead to enhancement of 
mRNA stability in an Akt dependent manner [Sheng et al., 2001]. Akt-dependent stabilization of mRNA 
was proposed for enhancement of CXCL8 expression by miR-155 in IB3-1 cells in a process that may 
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involve Akt regulation of RNA binding proteins [Schmidlin et al., 2004; Gherzi et al., 2006; 
Bhattacharyya et al., 2011]. Akt activity is elevated in numerous cancers and inhibition of Akt signaling 
in TMK-1 and MKN-28 gastric cancer cells reduced COX-2 expression [Thiel et al., 2006]. miR-155 
function has been investigated in numerous cancer cell lines. Knockdown of miR-155 in OCI-Ly3 cells 
reduced Akt activity [Huang et al., 2012]. In HT29 [Pu et al., 2012] and A549 [Zang et al., 2012] cells 
inhibition of miR-155 function reduced cell proliferation and increased cell sensitivity to cisplatin-
induced apoptosis. In MDA-MB-157 cells, inhibition of miR-155 induced apoptosis and reduced cell 
proliferation [Zheng et al., 2013]. Taken together, these studies indicate that miR-155 may regulate Akt 
signaling, proliferation, apoptosis, and chemoresistance in cancer. Furthermore, as miR-155 is elevated in 
cancers that exhibit elevated COX-2, it is plausible to hypothesize that miR-155 may be responsible, in 
part, for enhancing the expression of COX-2 in these cancers, even though miR-155 does not directly 
target human COX-2 mRNA. 
In support of this hypothesis, the effects observed with miR-155 inhibitors are similar to effects observed 
for COX-2 inhibition in cancer cell lines [Hu et al., 2003; Saikawa et al., 2004]. A reduction in COX-2 
expression would reduce COX-2 derived eicosanoid production and these eicosanoids have been shown 
to promote cancer cell proliferation, migration, apoptosis, and invasion in different studies [Wang and 
Dubois, 2010]. Thus, a miR-155 inhibitor may be beneficial in colorectal and other cancers. 
Abundant evidence demonstrates that the expression of COX-2 and miR-155 positively correlate in 
colorectal and other cancers. COX-2 expression is thought to be partly responsible for the tumorigenesis 
of colorectal cancer and miR-155 functional studies indicate that miR-155 inhibition reduces the 
tumorigenicity of various cancer cell lines. The mechanism responsible for miR-155 enhancement of 
COX-2 expression has not been identified yet, but miR-155 regulation of Akt signaling is a candidate 
pathway. As such, studies investigating miR-155 regulation of COX-2 expression in colorectal and other 
cancers are warranted. Such studies may reveal novel mechanisms responsible for COX-2 elevation and 
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promotion of tumorigenesis in these cancers and may lead to the development of novel RNA interference-
based drugs for treating these cancers. 
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